AngioDynamics
Yahoo Finance • last month
Angel One stock initiated with Neutral rating by UBS on regulatory risks
Investing.com - UBS initiated coverage on Angel One Ltd (NSE:ANGELONE) with a Neutral rating, citing regulatory uncertainties and valuation concerns. Angel One, India’s third-largest retail broker with 7.3 million NSE active clients as of... Full story
Yahoo Finance • 2 months ago
AngioDynamics stock maintains Buy rating at H.C. Wainwright after Q4 beat
Investing.com - H.C. Wainwright has reiterated its Buy rating and $16.00 price target on AngioDynamics (NASDAQ:ANGO) following the company’s fiscal fourth-quarter 2025 earnings report. According to InvestingPro data, the company maintain... Full story
Yahoo Finance • 2 months ago
AngioDynamics projects $305M–$310M FY26 sales as Med Tech drives double-digit growth
Earnings Call Insights: AngioDynamics (ANGO) Q4 2025 MANAGEMENT VIEW * James C. Clemmer, CEO, highlighted that "total revenue was $80.2 million representing growth of over 12% year-over-year, led by Med Tech growth of over 20% and Med... Full story
Yahoo Finance • 2 months ago
AngioDynamics (ANGO) Q4 2025 Earnings Transcript
Image source: The Motley Fool. DATE Tuesday, July 15, 2025 at 8:00 a.m. ET CALL PARTICIPANTS President and Chief Executive Officer — Jim Clemmer Executive Vice President and Chief Financial Officer — Steve Trowbridge Need a quote fro... Full story
Yahoo Finance • 2 months ago
Earnings call transcript: AngioDynamics Q4 2025 beats EPS forecast, stock rises
AngioDynamics Inc. (ANGO) reported its fourth-quarter fiscal 2025 results, showcasing a significant earnings beat and robust revenue growth. The company posted an earnings per share (EPS) of -$0.03, surpassing the forecasted -$0.12. Revenu... Full story
Yahoo Finance • 2 months ago
AngioDynamics Q4 2025 slides: Med Tech growth drives 12.7% revenue increase
AngioDynamics Inc (NASDAQ:ANGO) shares jumped 8.83% in premarket trading following the release of its fourth quarter and full-year fiscal 2025 results on July 15, 2025, which showed accelerating growth driven by its Med Tech segment and i... Full story
Yahoo Finance • 2 years ago
AngioDynamics, Inc. (NASDAQ:ANGO) Q4 2023 Earnings Call Transcript
AngioDynamics, Inc. (NASDAQ:ANGO) Q4 2023 Earnings Call Transcript July 12, 2023 AngioDynamics, Inc. misses on earnings expectations. Reported EPS is $0.01 EPS, expectations were $0.02. Operator: Good morning, and welcome to the AngioDyn... Full story
Yahoo Finance • 2 years ago
Why Shares of AngioDynamics Rose Friday
Shares of AngioDynamics (NASDAQ: ANGO) were up more than 8% Friday afternoon after rising as much as 9.1% on the news the medical technology company had sold some of its assets for $100 million. AngioDynamics makes vascular and oncology me... Full story
Yahoo Finance • 3 years ago
AngioDynamics to Report Fiscal 2023 Third Quarter Financial Results on March 30, 2023
LATHAM, N.Y., March 13, 2023--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment op... Full story
Yahoo Finance • 3 years ago
Wall Street Thinks This Obscure Growth Stock Could Soar 92% in 2023
As painful as market volatility can be, investors can leverage this to their advantage. The Nasdaq Composite is loaded with growth-oriented stocks. This is why the Nasdaq has plunged 35% year to date. Continue reading... Full story
Yahoo Finance • 3 years ago
Should You Buy This Under-the-Radar Growth Stock?
Earlier this month, AngioDynamics shared its financial results for the fourth quarter ended May 31. The Latham, New York-based medical device company topped both the analyst consensus for net sales and non-GAAP (adjusted) diluted earnings... Full story
Yahoo Finance • 3 years ago
3 Reasons to Consider Buying This Overlooked Medical Device Stock
The Nasdaq's sell-off looks to have given investors a buying opportunity in this little-known medical device stock.... Full story
Yahoo Finance • 3 years ago
AngioDynamics Reports Fiscal 2022 Third Quarter Financial Results; Reaffirms Fiscal Year 2022 Guidance
Fiscal 2022 Third Quarter Highlights Net sales of $74.0 million increased 3.9% compared to the prior-year quarter Med Tech grew 28.6% and Med Device declined 2.8% year over year Gross margin of 52.2% declined 190 basis points year over ye... Full story
